Fate Therapeutics

Biotech layoffs gather pace as industry downturn persists
Biotech layoffs gather pace as industry downturn persists
BioPharma Dive
layoffs
biotech
Amgen
Pfizer
Roche
Jounce Therapeutics
Fate Therapeutics
Molecular Templates
Sorrento Therapeutics
Flag link:
Fate hits reset as J&J cell therapy deal collapses, slashing pipeline and head count to stretch cash
Fate hits reset as J&J cell therapy deal collapses, slashing pipeline and head count to stretch cash
Fierce Biotech
Fate Therapeutics
JNJ
cell therapy
layoffs
Flag link:
Biotech’s key upcoming clinical results
Biotech’s key upcoming clinical results
EP Vantage
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
Flag link:
Nkarta: at least as good as Fate, at a tenth of the price
Nkarta: at least as good as Fate, at a tenth of the price
EP Vantage
Nkarta
Fate Therapeutics
natural killer cells
Flag link:
Fate delivers, up to a point
Fate delivers, up to a point
EP Vantage
Fate Therapeutics
natural killer cells
CAR-NK
FT596
Flag link:
Red-Hot Biotechs to Take Spotlight at Blood Disorder Meeting
Red-Hot Biotechs to Take Spotlight at Blood Disorder Meeting
Yahoo/Bloomberg
ASH2020
Trillium Therapeutics
CRISPR Therapeutics
Fate Therapeutics
Vertex Pharmaceuticals
Flag link:
J&J inks Fate deal to move into allogeneic CAR therapies
J&J inks Fate deal to move into allogeneic CAR therapies
Fierce Biotech
JNJ
Fate Therapeutics
CAR NK
CAR-T
cell therapies
drug development
Flag link:
Off-the-shelf cell therapy for cancer? Fate Therapeutics to make its case at ASH
Off-the-shelf cell therapy for cancer? Fate Therapeutics to make its case at ASH
Fierce Biotech
Fate Therapeutics
FDA
FT500
solid tumors
Flag link:
Fate Therapeutics Unveils Preclinical Findings of Newly-Identified Small Molecule Modulator Combination for Ex Vivo Programming of Mobilized Peripheral Blood
Fate Therapeutics Unveils Preclinical Findings of Newly-Identified Small Molecule Modulator Combination for Ex Vivo Programming of Mobilized Peripheral Blood
Yahoo/Globe NewsWire
Fate Therapeutics
hematologic cancers
Flag link:
Fate Therapeutics' Prohema in Phase II Study
Fate Therapeutics' Prohema in Phase II Study
Yahoo/Zacks.com
Prohema
Fate Therapeutics
stem cells
Flag link:
[video]Biotech IPOs With Big Partners
[video]Biotech IPOs With Big Partners
TheStreet.com
biotech
IPOs
Celgene
Amgen
Bind Therapeutics
Acceleron
Fate Therapeutics
Flag link:
Biotechs keep the cash pumping (for now) with more IPOs and ATMs
Biotechs keep the cash pumping (for now) with more IPOs and ATMs
Fierce Biotech
IPOs
Fate Therapeutics
biotech
ATMs
Flag link:
Matthew Herper And Robert Langreth On The Pharmaceutical Industry: in 2010, a major drug company will break up
Matthew Herper And Robert Langreth On The Pharmaceutical Industry: in 2010, a major drug company will break up
Forbes
JNJ
Medtronic
Pfizer
Vytorin
Boehringer Ingelheim
Elan
Eli Lilly
Fate Therapeutics
Gilead Sciences
Merck
Schering Plough
Wyeth
Flag link:
Fate Therapeutics Seals $30 M Series B, Gets Corporate Venture On Board
Fate Therapeutics Seals $30 M Series B, Gets Corporate Venture On Board
InVivo
Fate Therapeutics
Genzyme
Astellas
Flag link: